A Uturn by health watchdogs means leukaemia patients in Wales and England will get NHS access to a new cancer drug trialled in  Cardiff Those with the most common form of the blood cancer  Chronic lymphocytic leukaemia CLL  will now be able to have access to the drug Gazyvaro Cardiff University trials showed it can reduce the risk of death by  by preventing cancer cells multiplying Officials initially rejected the use of the drug two months ago The National Institute for Health and Care Excellence Nice has now provisionally approved the medicine following further analysis and the cost of the medicine being cut CLL affects  people in Wales and  in the UK Nices reversal on access to Gazyvaro means that clinicians will have an important new treatment option to help fight this common form of blood cancer said Prof Chris Fegan who led the trials at Cardiff University  Many patients with CLL often suffer from other medical conditions such as diabetes and heart disease making them unsuitable for more aggressive treatments  Gazyvaro is a tolerable option that can not only keep these patients in remission for significantly longer but offers a survival benefit over the current standard  The fact that patients across England and Wales will soon be able to routinely access Gazyvaro via the NHS will be welcome news to all those involved